Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough?
Seetal Dodd, Michael Bauer, André F. Carvalho, et al.
The World Journal of Biological Psychiatry (2020) Vol. 22, Iss. 7, pp. 483-494
Closed Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Major depressive disorder
Wolfgang Marx, Brenda W.J.H. Penninx, Marco Solmi, et al.
Nature Reviews Disease Primers (2023) Vol. 9, Iss. 1
Closed Access | Times Cited: 225
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Susan Ling, Felicia Ceban, Leanna M.W. Lui, et al.
CNS Drugs (2021) Vol. 36, Iss. 1, pp. 17-30
Closed Access | Times Cited: 80
Perspectives for therapy of treatment‐resistant depression
Mariusz Papp, Wiesław Jerzy Cubała, Łukasz Świȩcicki, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 17, pp. 4181-4200
Open Access | Times Cited: 61
DNA methylation changes in association with trauma-focused psychotherapy efficacy in treatment-resistant depression patients: a prospective longitudinal study
Rosana Carvalho Silva, Paolo Martini, Christa Hohoff, et al.
European journal of psychotraumatology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Recognizing depression as an inflammatory disease: The search for endotypes
Johannes Steffen, Nis Focken, Gürsel Çalışkan
AJP Cell Physiology (2024) Vol. 327, Iss. 1, pp. C205-C212
Closed Access | Times Cited: 9
Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: First results
Peter Stöhrmann, Godber Mathis Godbersen, Murray Bruce Reed, et al.
Journal of Affective Disorders (2023) Vol. 324, pp. 660-669
Open Access | Times Cited: 19
Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis
Nahathai Limveeraprajak, Sirapop Nakhawatchana, Apidsada Visukamol, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 132, pp. 110985-110985
Closed Access | Times Cited: 6
Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force
Ralph Kupka, Anne Duffy, Jan Scott, et al.
Bipolar Disorders (2021) Vol. 23, Iss. 7, pp. 659-678
Open Access | Times Cited: 38
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
Jason Ng, Joshua D. Rosenblat, Leanna M.W. Lui, et al.
Journal of Affective Disorders (2021) Vol. 293, pp. 285-294
Closed Access | Times Cited: 38
Care pathways, prescribing practices and treatment outcomes in major depressive disorder and treatment-resistant depression: retrospective, population-based cohort study
Sofia Pappa, Moulesh Shah, Sophie Young, et al.
BJPsych Open (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Going beyond risk factor: Childhood maltreatment and associated modifiable targets to improve life-long outcomes in mood disorders
Elizabeth Lippard, Charles B. Nemeroff
Pharmacology Biochemistry and Behavior (2022) Vol. 215, pp. 173361-173361
Open Access | Times Cited: 20
Development of Artificial Intelligence for Determining Major Depressive Disorder Based on Resting-State EEG and Single-Pulse Transcranial Magnetic Stimulation-Evoked EEG Indices
Yoshihiro Noda, Kento Sakaue, Masataka Wada, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 101-101
Open Access | Times Cited: 4
Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial
Anjali Punia, Sameeran S. Chate, Basavaraj R. Tubaki, et al.
Journal of Ayurveda and Integrative Medicine (2024) Vol. 15, Iss. 2, pp. 100896-100896
Open Access | Times Cited: 4
Aspirin-triggered lipoxin A4 reduces neuropathic pain and anxiety-like behaviours in male diabetic rats: antinociceptive enhancement by cannabinoid receptor agonists
Matheus Vinícius Ferreira, Carlos Henrique Alves Jesus, Joana Costa, et al.
European Journal of Pharmacology (2025) Vol. 989, pp. 177254-177254
Closed Access
A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
Yeşim Yeni, Zeynep Çakır, Ahmet Hacımüftüoğlu, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 246-246
Open Access | Times Cited: 17
Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression
Yiftach Roth, Faisal Munasifi, Steven A. Harvey, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 816-816
Open Access | Times Cited: 3
The pharmacological mechanism of chaihu-jia-longgu-muli-tang for treating depression: integrated meta-analysis and network pharmacology analysis
Yang Zhao, Dan Xu, Jing Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
G. Salvetti, Daniele Saccenti, Andrea Stefano Moro, et al.
Brain Sciences (2024) Vol. 14, Iss. 8, pp. 829-829
Open Access | Times Cited: 2
Difficult-To-Treat Depression. Scoping Review.
Walter Paganin, Sabrina Signorini, Antonio Sciarretta
PubMed (2023) Vol. 20, Iss. 3, pp. 173-182
Closed Access | Times Cited: 6
Viewpoint: Difficult-to-treat depression versus treatment-resistant depression: A new integrative perspective for managing depression
Walter Paganin
European Psychiatry (2023) Vol. 66, Iss. 1
Open Access | Times Cited: 6
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression
Raymond T. Yan, Tyler Marshall, Atul Khullar, et al.
Therapeutic Advances in Psychopharmacology (2024) Vol. 14
Open Access | Times Cited: 2
Case report: two cases of rhabdomyolysis following esketamine treatment
René Zeiss, Melissa Schweizer, Bernhard J. Connemann, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Genomic-Analysis-Oriented Drug Repurposing in the Search for Novel Antidepressants
Mohammad Hendra Setia Lesmana, Nguyen Quoc Khanh Le, Wei‐Che Chiu, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 1947-1947
Open Access | Times Cited: 10
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine
Roger S. McIntyre, Orly Lipsitz, Leanna M.W. Lui, et al.
Journal of Affective Disorders (2021) Vol. 294, pp. 592-596
Closed Access | Times Cited: 14
A New Option for Depressed Patients Who Do Not Respond to Antidepressant Medications
Michael E. Thase
American Journal of Psychiatry (2023) Vol. 180, Iss. 3, pp. 188-189
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top